Abstract:Therapeutic Advances in Chronic Disease, Volume 13, Issue , January-December 2022. Introduction:About one-third of primary biliary cholangitis (PBC) patients do not exhibit complete response to ursodeoxycholic acid (UDCA). Some of these patients were reported to benefit from the combination therapy of fibrates and UDCA, but more clinical evidence is required. In this study, we conducted a randomized, controlled trial on the safety and efficacy of fenofibrate in the treatment of patients with PBC.Methods:Forty-eight PBC patients with incomplete response to UDCA were enrolled and randomly assigned to two groups (24 in the experiment group and 24 in the control group). For the experimental group, the patients were administered 13–15 mg/kg/day UDCA in combination with 200 mg/day fenofibrate. For the control group, the patients continued to receive UDCA at 13–15 mg/kg/day. The patients were followed up for at least 12 months. The serum levels of alkaline phosphatase (ALP), gamma-glutamyl transferase (γ-GT), aspartate aminotransferase (AST), and other biochemical parameters were measured at 3, 6, and 12 months during the trial to assess patient conditions.Results:At 12 months, 20.8% of the patients in the experimental group had all three indexes of serum ALP, γ-GT, and total bilirubin normalized, while 0% of patients in the control group reached the primary outcome (difference, 20.8 percentage points; 95% CI, 4.6–37.0). 54.2% of the patients had normal ALP levels in the experimental group and 4.2% in the control group (difference, 50 percentage points; 95% CI, 28.5–71.5). The experimental group had greater improvement of ALP (p < 0.001) and IgG (p = 0.026) than the control group. The biochemical indexes of the patients in the experimental group also significantly improved during the treatment of fenofibrate.Conclusion:Addition of fenofibrate can improve biochemical indexes of PBC patients who had an incomplete response to UDCA. Reversible elevation of serum creatine and transaminases is observed in some patients.The trial was registered in the Chinese Clinical Trial Registry (ChiCTR) as ChiCTR1800020160 (protocol available online: http://www.chictr.org.cn/showproj.aspx?proj=32443).

Efficacy and Safety of Fenofibrate Add-on Therapy in Patients with Primary Biliary Cholangitis Refractory to Ursodeoxycholic Acid: A Retrospective Study and Updated Meta-Analysis

Combination Therapy Of Fenofibrate And Ursodeoxycholic Acid In Patients With Primary Biliary Cirrhosis Who Respond Incompletely To Udca Monotherapy: A Meta-Analysis

Efficacy and safety of fenofibrate addition therapy in patients with decompensated primary biliary cholangitis refractory to UDCA

Fenofibrate Normalizes Alkaline Phosphatase and Improves Long-Term Outcomes in Patients with Advanced Primary Biliary Cholangitis Refractory to Ursodeoxycholic Acid

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid

Efficacy and Safety of Fenofibrate Addition Therapy in Patients with Cirrhotic Primary Biliary Cholangitis with Incomplete Response to Ursodeoxycholic Acid

Efficacy of Fenofibrate in Chinese Patients with Primary Biliary Cirrhosis Partially Responding to Ursodeoxycholic Acid Therapy

Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Combination Therapy Of Bezafibrate And Ursodeoxycholic Acid For Primary Biliary Cirrhosis: A Meta-Analysis

Systematic Review and Meta-Analysis: Bezafibrate in Patients with Primary Biliary Cirrhosis.

A Multicenter, Randomized, Double-Blind Trial Comparing The Efficacy And Safety Of Tudca And Udca In Chinese Patients With Primary Biliary Cholangitis

Evidence for the Association Between IgG‐antimitochondrial Antibody and Biochemical Response to Ursodeoxycholic Acid Treatment in Primary Biliary Cholangitis

Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis A meta-analysis

Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis

Clinical Efficacy of Ursodesoxycholic Acid for the Treatment of Primary Biliary Cirrhosis: a Meta-analysis

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

Combination Therapy of Ursodeoxycholic Acid and Glucocorticoid and (or) Immunosuppressant in Patients with Primary Biliary Cholangitis

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine A protocol for systematic review and meta analysis